BL
BIIB icon

Balentine LLC’s Biogen BIIB Stock Holding History

Balentine LLC’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,145
Closed -$318K – 575
2023
Q1 		$318K Buy
1,145
+141
+14% +$39K 0.01% 397
2022
Q4 		$278K Buy
1,004
+52
+5% +$14.7K 0.01% 454
2022
Q3 		$254K Sell
952
-987
-51% -$210K 0.01% 429
2022
Q2 		$395K Buy
1,939
+302
+18% +$61.7K 0.01% 365
2022
Q1 		$345K Buy
+1,637
New +$356K 0.01% 390
2020
Q3 		– Sell
-194
Closed -$52K – 230
2020
Q2 		$52K Buy
194
+122
+169% +$36.7K ﹤0.01% 236
2020
Q1 		$23K Sell
72
-132
-65% -$40.1K ﹤0.01% 253
2019
Q4 		$61K Buy
204
+166
+437% +$46.1K ﹤0.01% 164
2019
Q3 		$9K Buy
38
+11
+41% +$2.56K ﹤0.01% 356
2019
Q2 		$6K Buy
+27
New +$6.23K ﹤0.01% 435
2019
Q1 		– Sell
-158
Closed -$48K – 436
2018
Q4 		$48K Hold
158
– – ﹤0.01% 117
2018
Q3 		$56K Buy
+158
New +$54.4K ﹤0.01% 62
2018
Q1 		– Sell
-714
Closed -$227K – 114
2017
Q4 		$227K Sell
714
-1
-0.1% -$321 0.02% 112
2017
Q3 		$224K Buy
715
+212
+42% +$62.8K 0.02% 106
2017
Q2 		$136K Hold
503
– – 0.01% 132
2017
Q1 		$138K Sell
503
-20
-4% -$5.66K 0.01% 131
2016
Q4 		$148K Buy
523
+83
+19% +$24.6K 0.02% 120
2016
Q3 		$138K Buy
440
+384
+686% +$114K 0.02% 104
2016
Q2 		$14K Buy
56
+37
+195% +$9.75K ﹤0.01% 288
2016
Q1 		$5K Sell
19
-4
-17% -$1.06K ﹤0.01% 302
2015
Q4 		$7K Buy
23
+6
+35% +$1.72K ﹤0.01% 362
2015
Q3 		$5K Sell
17
-168
-91% -$55.5K ﹤0.01% 403
2015
Q2 		$75K Sell
185
-84
-31% -$33.7K 0.01% 114
2015
Q1 		$114K Buy
+269
New +$106K 0.02% 85

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Balentine LLC's BIIB Position: Q2 2023 in Review

Balentine LLC sold out of Biogen (BIIB) in Q2 2023, closing a stake of 1,145 shares — an estimated $318K sold.

Balentine LLC first reported a position in BIIB in Q1 2015 and held it in 24 quarters. The position peaked at $395K in Q2 2022. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.

  • Balentine LLC reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
  • Balentine LLC sold 1,145 Biogen shares in Q2 2023, an estimated $318K.
  • Balentine LLC first reported a position in Biogen in Q1 2015 and held it in 24 quarters.
  • Balentine LLC's Biogen position peaked at $395K in Q2 2022.
  • 1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.

Based on Balentine LLC's 13F filing for Q2 2023, filed 14 Aug 2023.